STAT3 and cancer: Specifically, the effects of the drug on CLBL-1 were largely attributed to the interference on MYC target genes expression and several signaling pathways (JAK/STAT3, mTORC1, NF-kB) involved in cellular processes such as cell survival and proliferation, which are known to be dysregulated in cancer.